Table 1 Clinical data summary.
From: Proteasome inhibition as a potential therapeutic target in thymic cancer
TH/TC (n = 138) | ||
|---|---|---|
Sex | Male | 54 (39.1%) |
Female | 76 (55.1%) | |
Unknown | 8 (5.8%) | |
Age (y) | Median (IQR) | 62 (51–69) |
Range | 28-88 | |
Type | A | 12 (8.7%) |
AB | 45 (32.6%) | |
B1 | 17 (12.3%) | |
B2 | 35 (25.4%) | |
B3 | 19 (13.8%) | |
C | 10 (7.2%) | |
Masaoka-Koga | 1 | 30 (21.7%) |
2 | 50 (36.2%) | |
3 | 23 (16.7%) | |
4 | 10 (7.2%) | |
Unknown | 25 (18.1%) | |
Follow up (month) | Median (IQR) | 60 (30–93) |
Range | 1-252 | |
Death | 14 |
